PMID- 35110673
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220628
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Print)
IS  - 1434-5161 (Linking)
VI  - 67
IP  - 7
DP  - 2022 Jul
TI  - Identification of cytotoxic T cells and their T cell receptor sequences targeting 
      COVID-19 using MHC class I-binding peptides.
PG  - 411-419
LID - 10.1038/s10038-022-01013-4 [doi]
AB  - Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) was 
      first reported in China in December 2019, various variants have been identified 
      in different areas of the world such as United Kingdom (alpha), South Africa 
      (beta and omicron), Brazil (gamma), and India (delta). Some of SARS-CoV-2 
      variants, each of which is characterized by a unique mutation(s) in spike 
      protein, are concerned due to their high infectivity and the capability to escape 
      from neutralizing antibodies elicited by vaccinations. To identify peptide 
      epitopes that are derived from SARS-CoV-2 viral proteins and possibly induce 
      CD8(+) T cell immunity, we investigated SARS-CoV-2-derived peptides that are 
      likely to bind to major histocompatibility complex (MHC) class I molecules. We 
      identified a total of 15 peptides that bind to human leukocyte antigen 
      (HLA)-A*24:02, HLA-A*02:01, or HLA-A*02:06, and possibly induce cytotoxic T 
      lymphocytes (CTLs); thirteen of them corresponded to ORF1ab polyprotein, one 
      peptide to spike protein and the remaining one to membrane glycoprotein. CD8(+) T 
      cells that recognize these peptides were detected in peripheral blood samples in 
      three individuals recovered from COVID-19 as well as non-infected individuals. 
      Since most of these peptides are commonly conserved among other coronaviruses 
      including SARS-CoV and/or MERS-CoV, these might be useful to maintain T cell 
      responses to coronaviruses that are pandemic at present and will become the 
      future threat. We could define pairs of TRA and TRB sequences of nine CTL clones 
      that recognize SARS-CoV-2-derived peptides. We might use these SARS-CoV-2-derived 
      peptide-reactive TCR sequences for investigating the history of SARS-CoV-2 
      infection.
CI  - (c) 2022. The Author(s).
FAU - Hikichi, Tetsuro
AU  - Hikichi T
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan. t-hikichi@oncotherapy.co.jp.
FAU - Sakamoto, Michiko
AU  - Sakamoto M
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan.
FAU - Harada, Makiko
AU  - Harada M
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan.
FAU - Saito, Maki
AU  - Saito M
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan.
FAU - Yamane, Yuka
AU  - Yamane Y
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan.
FAU - Tokumura, Kimihisa
AU  - Tokumura K
AD  - OncoTherapy Science, Inc, Kawasaki, Kanagawa, Japan.
FAU - Nakamura, Yusuke
AU  - Nakamura Y
AD  - Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220202
PL  - England
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A Antigens)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - SARS-CoV-2 variants
SB  - IM
EIN - J Hum Genet. 2022 Feb 22;:. PMID: 35194135
MH  - CD8-Positive T-Lymphocytes
MH  - *COVID-19
MH  - Epitopes, T-Lymphocyte/genetics
MH  - HLA-A Antigens
MH  - Humans
MH  - Peptides/chemistry
MH  - Receptors, Antigen, T-Cell
MH  - *SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus/genetics
MH  - T-Lymphocytes, Cytotoxic
PMC - PMC8807680
COIS- TH, M. Sakamoto, MH, M. Saito, YY, and KT are employees of OncoTherapy Science, 
      Inc. YN is a stockholder and scientific advisor of OncoTherapy Science, Inc. TH 
      and YN are listed as the inventors on pending patent application that is related 
      to findings in this study.
EDAT- 2022/02/04 06:00
MHDA- 2022/06/29 06:00
PMCR- 2022/02/02
CRDT- 2022/02/03 05:31
PHST- 2021/11/24 00:00 [received]
PHST- 2022/01/03 00:00 [accepted]
PHST- 2021/12/21 00:00 [revised]
PHST- 2022/02/04 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2022/02/03 05:31 [entrez]
PHST- 2022/02/02 00:00 [pmc-release]
AID - 10.1038/s10038-022-01013-4 [pii]
AID - 1013 [pii]
AID - 10.1038/s10038-022-01013-4 [doi]
PST - ppublish
SO  - J Hum Genet. 2022 Jul;67(7):411-419. doi: 10.1038/s10038-022-01013-4. Epub 2022 
      Feb 2.